drugset / Trial / NCT00411203

Tamoxifen in Treatment of Acute Mania

NCT00411203

Phase 3 Completed 66 enrolled Stanley Medical Research Institute
RandomizedParallel-groupTriple-blindTreatment

Summary

Objective: Evidence indicates that the protein kinase C-PKC signaling cascade may be one of the direct targets in treatment of mania. The aim of this study is to investigate whether the PKC inhibitor-tamoxifen has anti-manic properties. Method: Bipolar subjects with manic/mixed episode were randomly assigned to receive either tamoxifen (80mg/day) or identical placebo tablets in 1:1 ratio for three weeks.

Timeline

Start
2003-04
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tamoxifen Small molecule 80 mg

Indications